Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ACE | P12821 | 10/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | REN | P00797 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2676753 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| SCHEMBL503522 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| SCHEMBL10835080 | 0.91 | SMN1; SMN2 (0.46) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| SCHEMBL14374305 | 0.86 | ACE (0.60) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| SCHEMBL12304830 | 0.86 | ACE (0.60) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| SCHEMBL4671537 | 0.85 | ACE (0.61) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| SCHEMBL4671532 | 0.85 | ACE (0.61) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| SCHEMBL3780597 | 0.83 | ACE (0.60) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| SCHEMBL4669921 | 0.83 | ACE (0.60) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| SCHEMBL4669890 | 0.83 | ACE (0.60) | SMN1; SMN2ACELMNAABCB11MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003045916-A1 | PROCESS FOR THE PREPARATION OF RAMIPRIL | BRANTFORD CHEMICALS INC. (CA) | 2003-06-05 | — | — | WO | claimed |
| EP-0219651-B1 | Inorganic acid salt of N-[1(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanylchloride and process for preparing the same | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1990-10-31 | — | — | EP | claimed |
| US-8445678-B2 | 2-quinoxalinol salen compounds and uses thereof | AUBURN UNIVERSITY (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120028362-A1 | 2-QUINOXALINOL SALEN COMPOUNDS AND USES THEREOF | AUBURN UNIVERSITY (US) | 2012-02-02 | — | — | US | disclosed |
| US-20090286968-A1 | 2-Quinoxalinol Salen Compounds and Uses Thereof | AUBURN UNIVERSITY (US) | 2009-11-19 | — | — | US | disclosed |
| EP-1861368-A1 | PROCESS FOR THE PREPARATION OF 2-AZABICYCLOÝ3.3.0¨OCTANE-3-CARBOXYLIC ACID DERIVATIVES | Evonik Degussa GmbH (DE) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006100168-A1 | PROCESS FOR THE PREPARATION OF 2-AZABICYCLO[3.3.0]OCTANE-3-CARBOXYLIC ACID DERIVATIVES | DEGUSSA GMBH (DE) | 2006-09-28 | — | — | WO | disclosed |
| EP-0967221-B1 | PROCESS FOR PREPARING PHARMACOLOGICALLY ACCEPTABLE SALTS OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANYL AMINO ACIDS | KANEKA CORP (JP) | 2005-05-25 | — | — | EP | disclosed |
| US-20050070543-A1 | Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-03-31 | — | — | US | disclosed |
| EP-0967221-A4 | PROCESS FOR PREPARING PHARMACOLOGICALLY ACCEPTABLE SALTS OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANYL AMINO ACIDS | KANEKA CORP (JP) | 2002-05-02 | — | — | EP | disclosed |
| US-5869671-A | Process for preparing an angiotensin converting enzyme inhibitor | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 1999-02-09 | — | — | US | disclosed |
| WO-1999005164-A1 | PROCESS FOR PREPARING PHARMACOLOGICALLY ACCEPTABLE SALTS OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANYL AMINO ACIDS | KANEKA CORPORATION (JP) | 1999-02-04 | — | — | WO | disclosed |
| WO-1996033984-A1 | N-SULFOXY ANHYDRIDES, A PROCESS FOR THE PREPARATION THEREOF AND ITS USE FOR THE PREPARATION OF BIOACTIVE SUBSTANCES HAVING ACE INHIBITORY ACTION | CENTRO GENESIS PARA LA INVESTIGACION, S.L. (ES) | 1996-10-31 | — | — | WO | disclosed |
| EP-0061768-B1 | N-AMIDO SUBSTITUTED DIPEPTIDES | USV PHARMACEUTICAL CORPORATION (US) | 1986-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286968-A1 | 2-Quinoxalinol Salen Compounds and Uses Thereof | NQO1, NQO2, SQOR | SMN1; SMN2 1013/4885ACE 1254/4885LMNA 706/4885 |
| US-20120028362-A1 | 2-QUINOXALINOL SALEN COMPOUNDS AND USES THEREOF | NQO1, NQO2, SQOR | SMN1; SMN2 1013/4885ACE 1254/4885LMNA 706/4885 |
| US-20050070543-A1 | Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage | ACE, ACE2, AGTR2 | SMN1; SMN2 467/4885ACE 1/4885LMNA 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.